Nitrate - Clopidogrel - Acute Coronary Syndrome

Impact of Intravenous Nitrate Treatment on Antiplatelet Effects of Clopidogrel in Acute Coronary Syndrome Patients: A Pilot Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06878638

Enrollment

Registered

2025-03-17

Start date

2023-02-01

Completion date

2024-04-01

Last updated

2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndromes

Keywords

Intravenous nitrate, clopidogrel, acute coronary syndrome

Brief summary

This study aims to investigate whether intravenous nitrate given during non-ST-elevation myocardial infarction (non-STEMI) affects the platelet inhibition of clopidogrel.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* diagnosed with non-STEMI * Patients aged 18 to 75 years * positive troponin levels, * blood pressure above 120/70 mmHg

Exclusion criteria

* Hemodynamically unstable and requiring urgent intervention, * ST elevation on electrocardiography, atrial fibrillation, * recurrent angina, * use of narcotic analgesics (e.g., morphine), nitrates and glycoprotein IIb/IIIa inhibitors during hospitalization, * history of coronary artery bypass graft (CABG) surgery, * active infection, * uncontrolled hypertension, * diabetes, cerebrovascular accident, Use P2Y12 inhibitor, proton pump inhibitor, oral anticoagulant, statin, CYP enzyme-inducing or inhibiting drugs at the time of admission, * active systemic disease (e.g., malignancy, thyroid disorders chronic inflammatory diseases, liver dysfunction), * left ventricular systolic dysfunction (ejection fraction \<50%), * glomerular filtration rate \<60 mL/min/1.73m2, * allergy to ASA or clopidogrel, coagulopathy, * platelet counts below 100,000/μl and hematocrit levels below 29%, or exceeding 52%.

Design outcomes

Primary

Measure	Time frame	Description
Platelet Reactivity Unit level	48 hours	Platelet Reactivity Unit \<208

Countries

Turkey (Türkiye)

Outcome results